Loading clinical trials...
Loading clinical trials...
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
Conditions
Interventions
Zalutumumab
Locations
48
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Loma Linda University Cancer Institute
Loma Linda, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Mountain States Tumor Institute
Boise, Idaho, United States
University Of Chicago Medical Center
Chicago, Illinois, United States
Ft. Wayne Medical Oncology/Hematology, Inc
Fort Wayne, Indiana, United States
Start Date
January 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2011
Last Updated
August 3, 2023
NCT07209189
NCT06477692
NCT04585750
NCT04915183
NCT07457346
NCT06636188
Lead Sponsor
Genmab
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions